State of Wyoming Sells 36,106 Shares of Indivior PLC (NASDAQ:INDV)

State of Wyoming cut its stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 47.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,738 shares of the company's stock after selling 36,106 shares during the quarter. State of Wyoming's holdings in Indivior were worth $494,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in Indivior during the fourth quarter valued at approximately $56,000. Lazard Asset Management LLC purchased a new stake in shares of Indivior in the fourth quarter worth $57,000. Stifel Financial Corp raised its position in shares of Indivior by 24.0% during the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock valued at $158,000 after purchasing an additional 2,450 shares during the period. Rathbones Group PLC lifted its stake in shares of Indivior by 11.6% during the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after buying an additional 1,483 shares in the last quarter. Finally, Gotham Asset Management LLC bought a new position in Indivior in the 4th quarter worth $325,000. 60.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on INDV. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Piper Sandler decreased their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research note on Thursday, March 6th. Finally, Rodman & Renshaw began coverage on Indivior in a report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target on the stock.

Indivior Stock Performance

INDV opened at $11.68 on Tuesday. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -33.37 and a beta of 0.98. The company has a fifty day moving average of $10.15 and a 200 day moving average of $10.66. Indivior PLC has a fifty-two week low of $7.33 and a fifty-two week high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The firm had revenue of $266.00 million during the quarter, compared to analyst estimates of $240.13 million. On average, equities research analysts forecast that Indivior PLC will post 1.22 earnings per share for the current year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.